Evidence map›Paper›PMID 31375768›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2020

Characterization of molecular signatures of supratentorial ependymomas.

Matthew Torre, Sanda Alexandrescu, Adrian M Dubuc, Azra H Ligon, Jason L Hornick, David M Meredith

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Matthew TorreDepartment of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Sanda AlexandrescuDepartment of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Adrian M DubucDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Azra H LigonDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Jason L HornickDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6475-8345
David M MeredithDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. dmmeredith@bwh.harvard.edu.ORCID http://orcid.org/0000-0002-7054-8624
Brigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ependymomas show poor correlation between World Health Organization grade and clinical outcome. A subgroup of supratentorial ependymomas are characterized by C11orf95-RELA fusions, presumed to be secondary to chromothripsis of chromosome 11, resulting in constitutive activation of the NF-κB signaling pathway and overexpression of cyclin D1, p65, and L1 cell adhesion molecule (L1CAM). These RELA-fused ependymomas are recognized as a separate, molecularly defined World Health Organization entity and might be associated with poor clinical outcome. In this study, we show that immunohistochemistry for NF-κB signaling components, such as L1CAM, p65, and cyclin D1, can help distinguish RELA-fused from non-RELA-fused supratentorial ependymomas. Furthermore, these three markers can reliably differentiate RELA-fused ependymomas from a variety of histologic mimics. Lastly, we report that RELA-fused ependymomas may be associated with different chromosomal copy number changes and molecular alterations compared to their non-RELA-fused counterparts, providing additional insight into the genetic pathogenesis of these tumors and potential targets for directed therapies.

Indexed as

AdolescentAdultBiomarkers, TumorChildEpendymomaFemaleHumansMaleMiddle AgedNF-kappa BOncogene FusionOncogene Proteins, FusionProteinsSupratentorial NeoplasmsTranscription Factor RelATranscription FactorsBiomarkers, TumorNF-kappa BOncogene Proteins, FusionProteinsRELA protein, humanTranscription Factor RelATranscription FactorsZFTA protein, human

Identifiers

PMID31375768
OpenAlexW2964652888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.